Subglottic secretion drainage,
does it really help with Reduced ventilator-associated pneumonia in mechanically ventilated adults?
research showsThe grade is B. Microbiologically confirmed pneumonia fell from 25.6% to 14.8% in Lacherade and from 17.6% to 8.8% in Damas. Absolute reductions of 10.8 and 8.8 percentage points are substantial. However, Tyco discounted Hi-Lo Evac tubes by 30% in Lacherade and Teleflex furnished the endotracheal tubes in Damas, so these were not counted as commercially independent replication, giving B with 70 points.
ads claimA tube designed to remove pooled secretions is a device feature, not proof of prevention. Here, randomized trials did show fewer microbiologically confirmed pneumonias, but that cannot be expanded into proven reductions in death or ventilation duration.
Useful facts when choosing a product
- A subglottic-drainage tube uses a separate port to remove secretions pooled above the cuff.
- Lacherade used intermittent manual drainage, whereas Damas used repeated suctioning, so protocols were not identical.
- A direct Korean distribution or use page for the device could not be verified.
- No duplicate ingredient-outcome verdict or reuse of either PMID/DOI pair was found in the existing list.
Chamgap Semantic Classification Code
Candidate index · review held
UNK.endotracheal-tubes-with-subglottic-secretion-drainage.UNK.ventilator-associated-pneumonia-in-mechanically-ventilated-adults.reduce.UNKUnknown > Endotracheal tubes with subglottic secretion drainage > Unknown > ventilator-associated pneumonia in mechanically ventilated adults > Reduction claim > Unknown
An automated migration candidate, not an issued permanent code; exact claim scope remains under review. This machine-generated migration candidate helps retrieval but is not a permanent assignment. The original verdict ID and URL remain authoritative.
What the research actually shows
Lacherade randomized 333 patients, 169 versus 164, and compared the registered primary endpoint of overall microbiologically confirmed pneumonia in all randomized patients. NCT00219661 and the paper used the same endpoint. Damas assigned 352 patients, 170 versus 182, across five ICUs in one hospital and measured microbiologically confirmed pneumonia. The author groups did not overlap and event reductions pointed in the same direction, but funding and in-kind support were not independent: Lacherade had nonprofit institutional funding while Tyco discounted Hi-Lo Evac tubes by 30%, and the Damas paper states, “Teleflex furnished the endotracheal tubes.” They were therefore not counted as independently funded replication. Damas trial registration, allocation-concealment implementation, and blinded assessment procedures were not established in the accessible record, counted as one reporting limitation.
Why this is classified as B (70)
A hard infection event fell by about 9 to 11 percentage points in two randomized trials. Tyco's 30% tube discount in Lacherade and Teleflex's provision of tubes in Damas meant funding and in-kind support were not independent; Damas registration and allocation details also remained limited. The trials were therefore not counted as independently funded replication, giving B with 70 points.
Counterpoint. This verdict applies to adults expected to require prolonged mechanical ventilation. It does not establish the same effect for every brief intubation, tracheostomy, suction pressure or interval, or branded device.
Rejudgment record. Cross-check applied — We cross-checked randomized denominators, microbiologically confirmed pneumonia events, and the NCT00219661 primary endpoint, and treated Tyco's 30% discount and Teleflex's provision of tubes as in-kind support rather than independent funding replication.
| Endpoint | H | Hard endpoint - actual events such as death |
| Replication | R1 | Single confirmatory trial |
| Independence | I1 | Mixed funding sources |
| Effect size | E+ | Meets the clinically important threshold |
Stored derived and displayed grades match; this is not a current recalculation or validity check (B).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Subglottic secretion drainage reduces microbiologically confirmed ventilator-associated pneumonia. | B | Two randomized trials found absolute reductions of 10.8 and 8.8 percentage points. |
| Subglottic secretion drainage reduces mortality in critical illness. | D | Across 17 trials, mortality RR was 0.93 (95% CI 0.84-1.03), without a significant reduction. |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Lacherade et al., AJRCCM 2010 | Four-center French randomized controlled trial | All 333: 169 drainage and 164 control | Nonprofit institutional funding; Tyco discounted Hi-Lo Evac tubes by 30% | Microbiologically confirmed ventilator-associated pneumonia | 25/169 (14.8%) versus 42/164 (25.6%); RR 0.58 (95% CI 0.37-0.90), P=.02 | Pivotal multicenter trial positive on its registered primary infection endpoint |
| Damas et al., Critical Care Medicine 2015 | Randomized controlled trial across five ICUs in one hospital | All 352: 170 suction and 182 control | “Teleflex furnished the endotracheal tubes” | Microbiologically confirmed ventilator-associated pneumonia | 15/170 (8.8%) versus 32/182 (17.6%), P=.018; adjusted OR 0.45 (95% CI 0.24-0.87) | Supportive trial by a separate team, with manufacturer in-kind support |
Receipt — 3 References
Of 3 cited sources, 1 had limited original-page access (blocked or summary-only) and were verified via index/summary, marked partial; the rest were verified at the original page. As of 2026-08-14.
Final verification and publication gate: Codex · Evidence date: 2026-08-14 · Corrections: none
Cite this verdict
[Chamgap] Subglottic secretion drainage x prevention of ventilator-associated pneumonia — Evidence Grade B·70. 3 cited sources checked. Source: https://chamgap.com/en/verdicts/immunity/subglottic-secretion-drainage-ventilator-associated-pneumonia/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.